GSK, hep B, Inmatics cancer therapy, Mark Cuban: The Readout

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Last spring, my colleague received an intriguing email from Mark Cuban. From there, a story was born. Read on for more.

The need-to-know this morning

Roivant and its subsidiary Priovant announced positive results across two Phase 3 studies of their drug Lisraya in non-infectious uveitis, an inflammatory eye disease that can lead to vision loss. Lisraya was recently approved to treat dermatomyositis, another inflammatory condition. Roivant said it will seek an expanded FDA approval for Lisraya in the first half of 2027.

Cuban’s Cost Plus Drugs is getting into rare disease

Mark Cuban’s Cost Plus Drugs, the online pharmacy that aims to lower drug costs by bypassing middlemen, has mostly been selling generic drugs. But the company is getting into a much more complicated field — experimental rare disease therapies.

STAT+ Exclusive Story